CERo Therapeutics (CEROW) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing engineered cellular immunotherapies for cancer. The company’s technology is designed to combine the tumor-recognition capabilities of T cells with the engulfing and destructive functions associated with macrophages, potentially enabling immune cells to attack cancer cells through multiple mechanisms.

CERo’s pipeline has included CER-1236, an autologous engineered T-cell therapy intended to target CD123, a protein expressed on certain blood cancers. The company has focused its initial development efforts on hematologic malignancies, including acute myeloid leukemia and related diseases.

The company is headquartered in the United States and serves the biopharmaceutical and oncology markets through research and clinical development activities. As a clinical-stage company, CERo’s therapies remain under development and are subject to clinical, regulatory and manufacturing requirements before they can be commercially available.

Key Stats

• Today's Range: $0.0021 to $0.0021
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.03
• Volume: N/A
• Average Volume: 38,976 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/07/2026
• Next Earnings (Estimated): 12/02/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CEROW
• CIK: 1870404
• Web: www.cero.bio
• Phone: 650-407-2376
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A